Figure 7.
PUMA mediates the antitumour effects of gilteritinib in vivo. A, Nude mice were injected s.c. with 5 × 106 WT or PUMA‐KO HCT116 cells. After 1 wk, mice were oral gavaged with 5 mg/kg gilteritinib or the vehicle control for 10 consecutive days. Tumour volume at indicated time‐points after treatment was calculated and plotted with P values, n = 6 in each group. Arrows indicate gilteritinib injection. B, Mice with WT HCT116 xenograft tumours were treated with 5 mg/kg gilteritinib or the vehicle for 5 consecutive days. The levels of indicated proteins in randomly selected tumours were analysed by Western blotting. C, Paraffin‐embedded sections of WT or PUMA‐KO tumour tissues from mice treated as in (B) were analysed by TUNEL staining. D, Paraffin‐embedded sections of WT or PUMA‐KO tumour tissues from mice treated as in (B) were analysed by activated caspase 3 staining. Results in (C) and (D) were expressed as means ± SD of three independent experiments. **P < .01